Updated overall survival after abiraterone acetate in mCRPC

According to a new article, to be published on line today in The Lancet, abiraterone acetate + prednisone provides a median overall survival benefit of 4.6 months compared to a placebo in men with metastatic, castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel-based chemotherapy. … READ MORE …

Small, Phase I combo trial suggests 3-year overall survival in men with mCRPC

A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer. … READ MORE …

New imaging technologies and management of CRPC

An article in the June issue of the journal Acta Oncologia discusses the potential of  newer types of imaging technology as methods to monitor the progression of disease in men with castrate-resistant prostate cancer (CRPC). … READ MORE –